DURABILITY PAS: The US Study for evaluating endovascular Treatments
of Lesions in the superficial femoral artery and proximal popliteal by
using the Protégé everflex nitinol Stent system post-approval study.
PI: Antonis Pratsos, MD
CRC: Lynn Sher, MBA I 484.337.4386
The objective of this post-approval study is to confirm the safety and
effectiveness of the Covidien / eV3 EverFlex™ self-expanding stent.
Patients with stenotic, restenotic or occluded lesions located in native
SFA or superficial femoral and proximal popliteal arteries suitable for
primary stenting may qualify for participation.
For additional information on cardiovascular clinical
trials, please call Ann Marie Chikowski, BSN, RN, CCRC, Clinical
Research Manager at 484.476.3030.
For more information, call 1.866.CALL.MLH.